Loading publications…
The last 5 uploaded publications
First-in-human results of terbium-161[ <sup>161</sup> Tb]Tb-PSMA-I&T radioligand treatment in patients with metastatic castration-resistant prostate cancer (VIOLET): A single-centre, single-arm, phase I/II study.
James Buteau, Louise Kostos, Price Jackson, Lachlan McIntosh, Ramin Alipour, Timothy Akhurst, Michal Eifer, Brittany Emmerson, Mohammad B. Haskali, Kerry Jewell, Raghava Kashyap, Grace Kong, Declan G. Murphy, Aravind S. Ravi Kumar, Javad Saghebi, Shahneen Sandhu, Ben Tran, Jing Xie, Arun Azad, Michael S. Hofman (2025). First-in-human results of terbium-161[ <sup>161</sup> Tb]Tb-PSMA-I&T radioligand treatment in patients with metastatic castration-resistant prostate cancer (VIOLET): A single-centre, single-arm, phase I/II study.. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.5010.
Article62 days ago<sup>177</sup> Lu-PSMA-617 with ipilimumab (ipi) and nivolumab (nivo) in metastatic castration-resistant prostate cancer (mCRPC): An investigator-initiated phase 2 trial (EVOLUTION; ANZUP2001).
Shahneen Sandhu, Shalini Subramaniam, Hayley Thomas, Thean Hsiang Tan, Jeffrey C. Goh, Nattakorn Dhiantravan, Andrew Weickhardt, Anthony M. Joshua, Ian Kirkwood, Sze Ting Lee, Craig Gedye, Andrew Nguyen, David A. Pattison, Ramin Alipour, Roslyn J. Francis, Michael S. Hofman, Andrew Martin, Martin R. Stockler, Ian D. Davis, Louise Emmett (2025). <sup>177</sup> Lu-PSMA-617 with ipilimumab (ipi) and nivolumab (nivo) in metastatic castration-resistant prostate cancer (mCRPC): An investigator-initiated phase 2 trial (EVOLUTION; ANZUP2001).. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.5016.
Article62 days agoFirst-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study
James Buteau, Louise Kostos, Price Jackson, Jing Xie, Mohammad B. Haskali, Ramin Alipour, Lachlan E McIntosh, Brittany Emmerson, Lisa L. MacFarlane, Claire A Martin, Joanna Chan, Sarah E. Williams, Kerry Jewell, Michal Eifer, A. Hamilton, W HARRIS, Tim Akhurst, Lewis Au, Anthony Cardin, Luc Furic, Raghava Kashyap, Grace Kong, Aravind S. Ravi Kumar, Declan G. Murphy, Rajeev Ravi, Javad Saghebi, Shahneen Sandhu, Ben Tran, Arun Azad, Michael S. Hofman (2025). First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study. , DOI: https://doi.org/10.1016/s1470-2045(25)00332-8.
Article62 days agoOverall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
Michael S. Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, James Buteau, Anthony M. Joshua, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian Kirkwood, Siobhan Ng, Roslyn J. Francis, Craig Gedye, Natalie Rutherford, Andrew Weickhardt, Andrew M. Scott, Sze-Ting Lee, Edmond M. Kwan, Arun Azad, Shakher Ramdave, Andrew D. Redfern, W A Macdonald, Alex Guminski, Edward Hsiao, Wei Chua, Peter Lin, Alison Yan Zhang, Martin R. Stockler, Scott Williams, Andrew Martin, Ian D. Davis, Tim Akhurst, Ramin Alipour, Dale L. Bailey, Patricia Banks, Alexis Beaulieu, Louise Campbell, Megan Crumbaker, Nattakorn Dhiantravan, Anis Hamid, Mohammad B. Haskali, Terry Hung, Grace Kong, Nick Lawrence, Jeremy Lewin, Michael McCarthy, Kate Moodie, Declan G. Murphy, Andrew Nguyen, David Pook, Aravind Ravi Kumar, Paul Roach, Peter Roselt, Javad Saghebi, Geoffrey Schembri, Lavinia Spain, Shalini Subramaniam, Sue Ping Thang, Paul Thomas, Ben Tran, Roslyn E. Wallace, Sonia Yip (2023). Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. , 25(1), DOI: https://doi.org/10.1016/s1470-2045(23)00529-6.
Article62 days agoEvolution: Phase II study of radionuclide <sup>177</sup>Lu-PSMA-617 therapy versus <sup>177</sup>Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001).
Shahneen Sandhu, Shalini Subramaniam, Michael S. Hofman, Martin R. Stockler, Andrew Martin, Izabella Pokorski, Jeffrey C. Goh, David A. Pattison, Nattakorn Dhiantravan, Craig Gedye, Natalie Rutherford, Anthony M. Joshua, Thean Hsiang Tan, Ian Kirkwood, Sze Ting Lee, Andrew Weickhardt, Ramin Alipour, Andrew Nguyen, Ian D. Davis, Louise Emmett (2023). Evolution: Phase II study of radionuclide <sup>177</sup>Lu-PSMA-617 therapy versus <sup>177</sup>Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001).. , 41(6_suppl), DOI: https://doi.org/10.1200/jco.2023.41.6_suppl.tps271.
Article62 days ago